Cellebrite DI Faces Shareholder Probe Following Stock Sell-Off

The investigation centers on a stark reversal in financial performance. During a February 2026 earnings call, CFO David Barter expressed confidence in the company's momentum, projecting annual recurring revenue (ARR) between $567 million and $573 million. However, by the second quarter, those expectations were downgraded to a range of $550 million to $560 million, with actual ARR performance appearing flat compared to the previous year.

Levi & Korsinsky, a firm recognized by the ISS Securities Class Action Services, is now reviewing whether these earlier disclosures constituted materially false or misleading statements. Investors who purchased CLBT securities and suffered financial losses are being asked to submit brokerage records for a potential recovery evaluation. The firm maintains that eligibility for the investigation depends on purchase dates rather than current share ownership, and they are handling the matter on a contingency basis.